IRIX News and Press, IRIDEX Corporation From 03/07/23

MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming 35 th Annual Roth Conference i...

Five Events at Booth #5 Discover the latest surgical techniques and outcomes published by the International MicroPulse TLT Consensus Panel. Watch Dr. Syril Dorairaj’s e-poster on prospective MicroPulse TLT dosimetry research outcomes. Demo Sweep Management Softw...

MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter a...

MOUNTAIN VIEW, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today provided preliminary unaudited operational and financial results for the fourth qu...

MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in a fireside chat with its coveri...

Shares of micro-cap eye-lasers procedure company Iridex ( NASDAQ: IRIX ) rose as much as 11.4% to $2.25 in Friday afternoon trading, after it reported a Q3 results beat and reaffirmed its FY 2022 guidance. The gains buck a recent weak run for IRIX stock, which has posted...

IRIDEX Corporation (IRIX) Q3 2022 Results Conference Call November 10, 2022 05:00 PM ET Company Participants David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital P...

IRIDEX press release ( NASDAQ: IRIX ): Q3 GAAP EPS of -$0.11 beats by $0.03 . Revenue of $14.64M (+10.4% Y/Y) beats by $0.77M . For further details see: IRIDEX GAAP EPS of -$0.11 beats by $0.03, revenue of $14.64M beats by $0.77M

MOUNTAIN VIEW, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 1, 2022. ...

MOUNTAIN VIEW, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quar...